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Purpose: Favorable outcome after cataract surgery depends on proper control of the inﬂammatory response
induced by cataract surgery. Pseudophakic cystoid macular edema is an important cause of visual decline after
uncomplicated cataract surgery.
Design: We compared the efﬁcacy of topical steroids with topical nonsteroidal anti-inﬂammatory drugs
(NSAIDs) in controlling inﬂammation and preventing pseudophakic cystoid macular edema (PCME) after un-
complicated cataract surgery.
Participants: Patients undergoing uncomplicated surgery for age-related cataract.
Methods: We performed a systematic literature search in Medline, CINAHL, Cochrane, and EMBASE da-
tabases to identify randomized trials published from 1996 onward comparing topical steroids with topical NSAIDs
in controlling inﬂammation and preventing PCME in patients undergoing phacoemulsiﬁcation with posterior
chamber intraocular lens implantation for age-related cataract.
Main Outcome Measures: Postoperative inﬂammation and pseudophakic cystoid macular edema.
Results: Fifteen randomized trials were identiﬁed. Postoperative inﬂammation was less in patients ran-
domized to NSAIDs. The prevalence of PCME was signiﬁcantly higher in the steroid group than in the NSAID
group: 3.8% versus 25.3% of patients, risk ratio 5.35 (95% conﬁdence interval, 2.94e9.76). There was no sta-
tistically signiﬁcant difference in the number of adverse events in the 2 treatment groups.
Conclusions: We found low to moderate quality of evidence that topical NSAIDs are more effective in
controlling postoperative inﬂammation after cataract surgery. We found high-quality evidence that topical NSAIDs
are more effective than topical steroids in preventing PCME. The use of topical NSAIDs was not associated with
an increased events. We recommend using topical NSAIDs to prevent inﬂammation and PCME after routine
cataract surgery. Ophthalmology 2014;121:1915-1924 ª 2014 by the American Academy of Ophthalmology.
Supplemental material is available at www.aaojournal.org.
Open access under CC BY-NC-ND license.Cataract surgery is one of the most frequently performed
elective surgical procedures in developed countries. The
surgical methods have improved signiﬁcantly over the
years, thus lowering the risk of complications and raising
patients’ and surgeons’ expectations of a successful visual
outcome. In patients without other eye diseases, 20/20 vi-
sual outcome is a realistic expectation.
Like other types of surgery, cataract surgery induces a
surgical inﬂammatory response. Uncontrolled inﬂammation
may lead to serious side effects, such as posterior synechia,
uveitis, and secondary glaucoma. Management of inﬂam-
mation is thus a mainstay in modern cataract surgery.
Currently, 2 drug groups are available to control ocular
inﬂammation: steroids and nonsteroidal anti-inﬂammatory
drugs (NSAIDs). Steroids are potent anti-inﬂammatory
agents that work by acting on a number of intercellular 2014 by the American Academy of Ophthalmology
Published by Elsevier Inc. Open access under CC BY-NC-ND license.inﬂammatory mediators, and NSAIDs work by inhibiting
the cyclooxygenase enzymes. The cyclooxygenase enzymes
catalyze the formation of prostaglandins and thromboxanes.
Prostaglandins mediate inﬂammatory reactions. Preventing
the formation of prostaglandins reduces the inﬂammatory
process.
Pseudophakic cystoid macular edema (PCME, also
termed “IrvineeGass syndrome”) is a swelling of the fovea
due to ﬂuid accumulation occurring a few weeks to months
after cataract surgery. It is the most common cause of visual
decline after cataract surgery. The prevalence of PCME
varies from study to study depending on how PCME is
deﬁned. By using ﬂuorescein angiography, a prevalence of
PCME of up to 20% has been reported,1,2 whereas only 2%
were diagnosed with PCME when loss of visual acuity was
required to establish the diagnosis.1,3 Usually, PCME is1915http://dx.doi.org/10.1016/j.ophtha.2014.04.035
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become chronic, resulting in permanent visual loss.
The cause of PCME is thought to be an increased
vascular permeability induced by inﬂammatory mediators
such as prostaglandins. Some reports have found an
increased risk of PCME in patients using prostaglandin
analogs to control glaucoma.4,5 There is a tendency toward a
higher prevalence of PCME in patients with increased
postoperative inﬂammation.2 The relationship between
inﬂammation and PCME is further supported by the 3-
fold increase in the risk of PCME in patients with a his-
tory of uveitis.6 Macular thickness is greater in patients with
complicated cataract surgery compared with uncomplicated
surgery.7 Increased surgical trauma such as iatrogenic iris
lesion increases the risk of PCME.1 Furthermore, the risk
of PCME is increased in patients with a history of retinal
venous occlusion or an epiretinal membrane,3 whereas
posterior vitreous detachment seems to protect against
PCME.1
Deciding which anti-inﬂammatory agent to use as stan-
dard in patients undergoing cataract surgery is important to
ensure a favorable outcome. The present systematic review
compares the efﬁcacy of topical steroids with that of topical
NSAIDs in reducing postoperative inﬂammation and pre-
venting PCME. The study was initiated by the Danish
Health and Medicines Authorities to formulate evidence-
based national guidelines on the management of age-
related cataract.Sources and Methods of Literature Search
We performed this systematic review and subsequent meta-
analyses on the basis of the principles described in the Grades of
Recommendation, Assessment, Development, and Evaluation
(GRADE) approach.8 We ﬁrst deﬁned the topic of the systematic
review using the Patient, Intervention, Comparison, and
Outcome approach.9 We compared the efﬁcacy of steroid eye
drops (Intervention) with NSAID eye drops (Comparison) in
preventing inﬂammation (Outcome) and PCME (Outcome) after
uncomplicated cataract surgery by phacoemulsiﬁcation with
posterior chamber intraocular lens implantation in patients with
age-related cataract (Patients). We included only randomized
controlled trials in the meta-analysis. We excluded references
comparing other types of interventions or surgical methods. We
did not compare the additive effects of steroids plus NSAIDs
versus steroids or NSAIDs alone because a Cochrane protocol
covers this topic.10 We included all types of topical steroids and
topical NSAIDs in the review.
For outcomes, we analyzed the number of cells and ﬂare as
inﬂammation markers measured by laser ﬂare-cell photometry or
slit-lamp evaluation, PCME as deﬁned in the included studies
(ﬂuorescein angiograms or optical coherence tomography [OCT]),
and best-corrected distance visual acuity at last follow-up after
cataract surgery. The time point for evaluation of inﬂammation
was at 2 to 8 days post-surgery. The time point for evaluation of
PCME was as chosen by the included studies. Risks and adverse
events associated with the use of topical eye drops were also
quantiﬁed using the number of complications as deﬁned in the
included studies and the intraocular pressure (IOP) after the
treatment period.
We performed a systematic literature search in April 2013 in the
EMBASE, Medline (Ovid), Cochrane Library, and CINAHL1916databases. An example of the search strategy for the EMBASE
database is provided in Appendix 1 (available at
www.aaojournal.org). Similar search strategies were used for the
other databases. The search was limited to references published
from 1996 and onward in the English or Scandinavian languages.
The year limitation was chosen to ensure that only studies using
surgical methods that were comparable to modern date methods
were included. The literature search was performed by a trained
information specialist (Birgitte Holm Pedersen). We did not
search trial registries for unpublished trials. According to Danish
law, no institutional review board approval was required for the
study.
We assessed the risk of bias of each included study using the
Cochrane risk of bias tool11 in the Review Manager Software
(Review Manager [RevMan] version 5.2. Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration,
2012, available at: http://tech.cochrane.org/revman/download,
Accessed April 2013). In short, the Cochrane risk of bias tool
assesses risk of bias associated with the selection of patients
(randomization or patient allocation and concealment of
allocation), study performance (blinding of patients and
personnel), measurement of outcomes (blinding of outcome
assessment), attrition of data (e.g., missing patients or dropouts),
reporting of study ﬁndings (selective outcome reporting), or other
types of bias related to the study design that could affect the
internal validity. This part of the systematic review was done
independently by 2 reviewers (BT and KJJ). Disagreement was
resolved through discussion and consensus.
We evaluated the quality of the evidence for each prespeciﬁed
outcome across the included studies using the GRADE system in the
Grade Proﬁler Software (version 3.6, 2011, available at: http://
tech.cochrane.org/revman/other-resources/gradepro/download, Acc-
essed April 2013). We analyzed each outcome for study limitations
that could affect the outcome (i.e., risk of bias),12 inconsistency
(different results between studies),13 indirectness (was the study
population and intervention comparable to the patient population
and intervention that is relevant to users [external validity], use of
surrogate measures),14 imprecision (large conﬁdence intervals [CIs]
or the lack of statistical strength),15 and risk of publication bias
(small number of studies or included patients, lack of reporting of
negative ﬁndings).16 We upgraded or downgraded the quality of the
evidence for each of the prespeciﬁed outcomes on the basis of the
assessment of each of the limitations mentioned earlier.
We analyzed continuous outcome data using mean difference
and dichotomous outcome data using risk ratios. We used the
Review Manager 5 Software to calculate estimates of overall
treatment effects and random-effects models to calculate pooled
estimates of effects.Summary of Evidence
Our systematic literature search returned 352 titles and ab-
stracts, and 82 references were identiﬁed by other sources.
Titles and abstracts were reviewed by 1 reviewer (LK), and
115 references were judged to be of potential interest by the
reviewer. These were collected in full text, and 15 ran-
domized controlled clinical trials met our inclusion
criteria.17e31 All included studies excluded patients with
ocular diseases (e.g., glaucoma, uveitis, previous surgery, or
trauma), which might affect the outcome after surgery.
Seven of the included trials compared the prophylactic ef-
fect of topical steroids and NSAIDs on the occurrence of
cystoid macular edema after cataract surgery.17,25e28,31
Table 1. Overview of Interventions in Included Studies
Study ID Steroid NSAID Dosing
Asano et al 200817 Betamethasone sodium 0.1% Diclofenac sodium 0.1% 1 drop 3 hrs, 2 hrs, 1 hr, and 1/2
hr preoperatively and
then 3/day for 8 wks
Demco et al 199718 Prednisolone acetate 1.0% Diclofenac sodium 0.1% 4/day from the ﬁrst postoperative day
El-Harazi et al 199819 Prednisolone acetate 1% Diclofenac sodium 0.1% 4/day from the ﬁrst postoperative
day for 1 wk, then 2/day for 3 wks
El-Harazi 1998 (steriod B)19 Prednisolone acetate 1% Ketorolac tromethamine 0.5% 4/day from the ﬁrst postoperative
day for 1 wk, then 2/day for 3 wks
Endo et al 201020 Betamethasone sodium
phosphate for 1 wk
and ﬂuorometholone
0.1% for 5 wks
Bromfenac Steroid group: 4/day for 5 wks
NSAID group: 2/day for 5 wks
Hirneiss et al 200521 Prednisolone acetate 1% Ketorolac tromethamine 0.5% 6 drops/day on days 1e3,
5 drops/day on days 4e10,
4 drops/day on days 11e14,
3 drops/day on days 15e18,
2 drops/day on days 19e21,
1 drop/day on days 22e28
Hirneiss et al 2005 B21 Rimexolone 1% Ketorolac tromethamine 0.5% 6 drops/day on days 1e3,
5 drops/day on days 4e10,
4 drops/day on days 11e14,
3 drops/day on days 15e18,
2 drops/day on days 19e21,
1 drop/day on days 22e28
Holzer et al 200222 Loteprednol etabonate 0.5% Ketorolac tromethamine 0.5% 1 drop 4/day the ﬁrst week
after surgery, then 1 drop 2/day for
the remainder of the study
Laurell and Zetterstrom 200223 Dexamethasone phosphate 0.1% Diclofenac sodium 0.1% 4/day the ﬁrst week, then 2/day for 3 wks
Missotten et al 200124 Dexamethasone 0.1% Indomethacin 0.1% 4/day beginning the day before surgery
and for 30 days postoperatively
Miyake et al 200028 Fluorometholone 0.1% Diclofenac 0.1% 1 drop 3 hrs, 2 hrs, 1 hr, and 1/2 hr before
surgery, then 3/day for 8 wks
Miyake et al 200727 Fluorometholone 0.1% Diclofenac 0.1% 1 drop 3 hrs, 2 hrs, 1 hr, and 1/2 hr before
surgery, then 3/day for 5 wks
Miyake et al 201126 Fluorometholone 0.1% Nepafenac 0.1% 3/day starting the day before surgery
until 5 wks postoperatively
Miyanaga et al 200925 Betamethasone 0.1%
for 1 mo, then
ﬂuorometholone 0.1%
for 1 mo
Bromfenac 0.1% Steroid group: 4/day for 8 wks
NSAID group: 2/day for 8 wks
Roberts and Brennan 199529 Prednisolone acetate 1% Diclofenac 0.1% 4/day for 1 wk, then 2/day for 3 wks
Solomon et al 200130 Rimexolone 1% Ketorolac tromethamine 0.5% 4/day beginning immediately after surgery
Wang et al 201331 Fluorometholone 0.1% Bromfenac sodium 0.1% Steroid group: 3/day for 1 mo
NSAID group: 2/day for 1e2 mos
Wang et al 2013 B31 Dexamethasone 0.1% Bromfenac sodium 0.1% Steroid group: 3/day for 1 mo
NSAID group: 2/day for 1e2 mos
NSAID ¼ nonsteroidal anti-inﬂammatory drug.
Kessel et al  Topical Steroids versus NSAIDs after Cataract SurgeryCharacteristics and risk of bias assessments of the included
studies are provided in Appendix 2 (available at
www.aaojournal.org). A list of excluded studies with
reasons for exclusion is provided in Appendix 3 (available
at www.aaojournal.org).
The included studies compared different types of steroids
with different types of NSAIDs. Table 1 provides an
overview of the included interventions and comparisons.
Prevention of Inﬂammation
The anti-inﬂammatory effect of topical NSAIDs and steroid
eye drops after cataract surgery was evaluated by examining
signs of intraocular inﬂammation: cells and ﬂare. Somestudies used laser cell-ﬂare photometry, and others used a
slit-lamp to identify inﬂammatory signs. Those studies that
used a slit-lamp did not consistently use comparable grading
systems, which made their inclusion in a meta-analysis
difﬁcult. For this reason, we chose to include only studies
evaluating inﬂammation by laser cell-ﬂare photometry in
our meta-analysis. All included studies used a study design
in which patients with a history of ocular inﬂammation
(iritis or uveitis) had been excluded from the study.
Inﬂammation Measured as Number of Cells
Only 4 of the included studies reported on the number of
cells as evaluated by laser cell-ﬂare photometry. We did not1917
Figure 1. Forest plot comparing the effect of topical steroid versus nonsteroidal anti-inﬂammatory drug (NSAID) eye drops on inﬂammation quantiﬁed as
the number of cells detected by laser cell-ﬂare photometry (photons/ms) at 1 week postoperatively. CI ¼ conﬁdence interval; df ¼ degrees of freedom; IV ¼
inverse variance; SD ¼ standard deviation.
Ophthalmology Volume 121, Number 10, October 2014ﬁnd a signiﬁcant difference in the number of cells detected
by laser cell-ﬂare photometry at 1 week postoperatively
between patients randomized to steroid or NSAID eye
drops. The mean difference was 1.01 (95% CI, 0.78 to
2.81; I2 29%). All 4 studies used steroid eye drops of low to
medium potency: prednisolone,19,29 loteprednol,22 or
ﬂuorometholone.28 The meta-analysis is shown in Figure 1.
Inﬂammation Measured as Flare
We found that topical NSAIDs were more effective than
steroid eye drops in reducing postoperative inﬂammation
measured as the amount of ﬂare by laser ﬂare photometry at
1 week postoperatively. The mean difference was 6.88 (95%
CI, 3.26e10.50; I2 89%). However, steroids of medium to
high potency (betamethasone, dexamethasone, loteprednol,
and prednisolone) were not signiﬁcantly different fromFigure 2. Topical steroid versus nonsteroidal anti-inﬂammatory drug (NSAID)
photometry (photons/ms) at 1 week after cataract surgery. CI ¼ conﬁdence i
deviation.
1918NSAIDs in controlling inﬂammation, whereas steroids of
low potency (ﬂuorometholone) were signiﬁcantly less
effective in controlling inﬂammation (Fig 2).
Pseudophakic Cystoid Macular Edema
We identiﬁed 7 randomized clinical trials that compared the
prevalence of PCME after topical steroid or
NSAID.17,20,25e28,31 One of the 7 studies reported foveal
thickness measured by OCT in patients with diabetes mel-
litus and was excluded from the analysis of PCME.20 Thus,
all 6 studies included in this meta-analysis used a study
design in which patients with a history of uveitis, diabetes,
or diabetic retinopathy were excluded from participation.
Four studies evaluated the presence of PCME by ﬂuorescein
angiography 5 weeks after cataract surgery.17,26e28 The
remaining 2 studies evaluated the presence of PCME byeye drops on preventing postoperative inﬂammation quantiﬁed by laser ﬂare
nterval; df ¼ degrees of freedom; IV ¼ inverse variance; SD ¼ standard
Figure 3. Topical steroid versus nonsteroidal anti-inﬂammatory drug (NSAID) for preventing cystoid macular edema at 1 month after cataract surgery. CI ¼
conﬁdence interval; df ¼ degrees of freedom; M-H ¼ ManteleHaenszel.
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tients received highly potent steroids (betamethasone or
dexamethasone),17,25,31 whereas others received a less
potent steroid (ﬂuorometholone).26e28 In the steroid group,
25.3% of patients had PCME at 1 month versus 3.8% in the
NSAID group (risk ratio, 5.35; 95% CI, 2.94e9.76; I2 0%).
Potent and weaker steroids were both less effective than
NSAIDs, and there was no indication that potent steroids
were more effective than weaker steroids (P ¼ 0.74, test for
subgroup difference) (Fig 3).
Visual Acuity after Cataract Surgery
Four studies reported the visual acuity at the longest follow-
up 6 to 8 weeks after cataract surgery.17,20,25,31 Best-
corrected distance visual acuity was on average 0.02
logarithm of theminimumangle of resolution (95%CI,0.01
to 0.05; I2 72%) better in theNSAID group comparedwith the
steroid group. This corresponds to 1 letter on the Early
Treatment of Diabetic Retinopathy Study chart. The differ-
ence was not statistically signiﬁcant (P ¼ 0.19) (Fig 4).Figure 4. Final visual acuity (logarithm of the minimum angle of resolution [lo
randomized to topical steroids or topical nonsteroidal anti-inﬂammatory drug (N
variance; SD ¼ standard deviation.Risks and Adverse Events
Both topical steroids and topical NSAIDs can be associated
with harms. Twelve of the included studies reported the
number of harms in both treatment groups.17e19,21e24,26,28e31
Harms ranged from bitter taste to uveitis with hypopyon, but
the majority of harms were simply reported as “complica-
tions” without further description. We evaluated the number
of harms as reported in the included studies in addition to
study withdrawals due to harms of the treatment. The overall
prevalence of harms was 5.5% in the steroid group and 6.6%
in the NSAID group. The difference was not signiﬁcant (risk
ratio, 0.76; 95% CI, 0.50e1.15; I2 0%) (Fig 5).
Nonsteroidal anti-inﬂammatory drugs have been associ-
ated with corneal melts, and although all patients had an
anterior segment slit-lamp examination postoperatively,
none of the studies speciﬁcally reported melts; thus, we
could not perform a meta-analysis for complications spe-
ciﬁcally related to NSAID use.
Steroids are known to be associated with a risk of
increased IOP. As shown in Figure 6, patients who weregMAR]) at the last follow-up 6 or 8 weeks after cataract surgery in patients
SAIDs). CI ¼ conﬁdence interval; df ¼ degrees of freedom; IV ¼ inverse
1919
Figure 5. Number of complications as deﬁned in the included studies. CI ¼ conﬁdence interval; df ¼ degrees of freedom; M-H ¼ ManteleHaenszel;
NSAID ¼ nonsteroidal anti-inﬂammatory drug.
Ophthalmology Volume 121, Number 10, October 2014randomized to topical steroids had a statistically signiﬁcant
higher IOP at the end of the treatment period than patients
randomized to topical NSAIDs. The mean difference was
0.50 mmHg (95% CI, 0.05e0.96; I2 51%). The treatment
period ranged from 28 days to 2 months. The IOP was
highest in the group receiving the most potent steroids
and lowest in the group receiving the least potent steroid,Figure 6. The intraocular pressure (IOP) at the end of the treatment period (2
topical nonsteroidal anti-inﬂammatory drug (NSAID) after cataract surgery. CI
1920but the difference between the groups was not statistically
signiﬁcant (P ¼ 0.42 for subgroup difference). Two
studies reported the number of patients with a marked
increase in IOP.21,23 One study21 identiﬁed 1 steroid
responder, who was excluded from the rest of the
analysis. The other study did not ﬁnd any steroid
responders.238 days to 8 weeks duration) in patients randomized to topical steroid versus
¼ conﬁdence interval; df ¼ degrees of freedom; IV ¼ inverse variance.
Table 2. Summary of Findings and Assessment of the Quality of the Evidence
Outcomes
Illustrative Comparative Risks* (95% CI)
Relative Effect
(95% CI)
No of Participants
(Studies)
Quality of the
Evidence (Grade)
Assumed Risk Corresponding Risk
NSAIDs Steroids
Cells 1 wk postoperatively
by laser cell photometry
Mean cells 1 wk postoperatively
by laser cell photometry in the
intervention groups were
1.01 higher (0.78
lower to 2.81 higher)
269 (4 studies) 4442 Moderatey
Flare 1 wk postoperatively
by laser photometry
Mean ﬂare 1 wk postoperatively
by laser photometry in the
intervention groups was 6.88
higher (3.26 to 10.5 higher)
931 (11 studies) 4422 Lowyz
PCME 38/1000 201/1000 (110e366) RR 5.35 (2.94e9.76) 521 (6 studies) 4444 Highyx
Visual acuity at last follow-up,
logMAR
Mean visual acuity at last follow-
up in the intervention groups
was 0.02 higher (0.01 lower to
0.05 higher)
344 (4 studies) 4422 Lowyk
Adverse events as deﬁned by
study
66/1000 50/1000 (33e76) RR 0.76 (0.50e1.15) 1207 (12 studies) 4442 Moderatey
IOP at the end of treatment Mean IOP at the end of treatment
in the intervention groups was
0.50 higher (0.05 to 0.96 higher)
969 (12 studies) 4442 Moderatey{
CI ¼ conﬁdence interval; IOP ¼ intraocular pressure; logMAR ¼ logarithm of the minimum angle of resolution; PCME ¼ pseudophakic cystoid macular
edema; RR ¼ risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conﬁdence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our conﬁdence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our conﬁdence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
yRisk of selection bias.
zI2 ¼ 89%.
xRisk ratio 6.
kI2 ¼ 72%.
{An effect cannot be ruled out.
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The quality of the evidence for each of the outcomes
described (number of cells, ﬂare, PCME, visual acuity,
adverse events, and IOP) was assessed according to the
criteria deﬁned in the GRADE system.32 A summary of our
ﬁndings and the quality of the evidence are presented in
Table 2.
Inﬂammation, evaluated as the number of cells and ﬂare
by laser photometry, was less pronounced in the NSAID
group after 1 week of treatment. The quality of the evidence
was low to moderate. We downgraded the quality of the
evidence because of the risks of selection bias and hetero-
geneity between studies.
Pseudophakic cystoid macular edema was approximately
7 times as prevalent in the steroid group compared with the
NSAID group. The quality of the evidence was high. We
ﬁrst downgraded the quality of the evidence because of risk
of selection bias, and then we upgraded because of the large
difference in the prevalences.
There was no signiﬁcant difference in visual acuity at the
end of the treatment period in the groups randomized to
topical steroid or NSAIDs. The quality of the evidence waslow. We downgraded the quality because of risk of selection
bias in the included studies and large heterogeneity between
study results.
There was no difference in the number of adverse events
as deﬁned in the included studies. We downgraded the
quality of the evidence to moderate because of risk of se-
lection bias. The IOP was higher in the steroid group at the
end of the treatment period. The quality of the evidence was
downgraded to moderate because of risk of selection bias in
the included studies.Discussion
We performed a systematic review and meta-analyses to
compare the effect of topical steroids with topical NSAIDs
in controlling inﬂammation and preventing PCME after
cataract surgery. We found that topical NSAIDs were more
effective than even potent topical steroids. Our conclusion
concerning control of inﬂammation is based on 931 patients
randomized to topical steroids or NSAIDs, and our
conclusion concerning PCME is based on 521 randomized1921
Ophthalmology Volume 121, Number 10, October 2014patients. Thus, a large number of patients needs to be
included in future studies to change our conclusion.
We did not ﬁnd evidence for an increased risk of adverse
events with the use of NSAIDs, but previous reports have
indicated that prolonged use of topical NSAIDs may be
associated with a risk of corneal melts33 and impaired
corneal wound healing.34
We found high-quality evidence that topical NSAIDs
are more effective in preventing PCME than topical ste-
roids. Pseudophakic cystoid macular edema was 6 to 7
times more prevalent in patients randomized to topical
steroids compared with topical NSAIDs when evaluated by
ﬂuorescein angiography or OCT at 4 to 5 weeks after
cataract surgery. Macular thickness, as assessed by OCT in
patients without PCME, peaks at approximately 4 to 6
weeks postoperatively.35e37 Thus, it is not likely that many
cases of PCME were missed in the included studies. Our
ﬁnding is supported by earlier ﬂuorophotometric ﬁndings
of an earlier reestablishment of the bloodeaqueous barrier
in NSAID-treated patients compared with steroid-treated
patients.38
The quality of the evidence concerning prevention of
PCME was high, although it may be considered a weakness
in the generalizability of results that all included studies
came from Asia; 1 study came from China,31 4 studies came
from the same Japanese group,17,26e28 and the last study
came from a second Japanese group.25 Although there is no
reason to suspect a racial difference in the postoperative
inﬂammatory response, it would be appreciated if the
ﬁndings could be reproduced in a non-Asian population.
Currently, a multicenter study comparing the effect of topical
bromfenac with dexamethasone for the prevention of PCME
is being conducted in cooperation with the European Society
of Cataract and Refractive Surgeons (available at: http://
www.clinicaltrialsregister.eu/ctr-search/trial/2012-004873-
14/NL, Accessed July 2013).
The studies included in our meta-analyses compared
different types of topical steroids with different types of
NSAIDs. Steroids are known to be of different potency,
with betamethasone and dexamethasone being the most
potent and ﬂuorometholone and rimexolone being the least
potent. Diﬂuprednate is a new and possibly more potent
steroid, but its effect in managing inﬂammation or pre-
venting PCME after cataract surgery has not been compared
with NSAIDs. We grouped our meta-analyses according to
the strength of the steroids but did not ﬁnd that the most
potent steroids were signiﬁcantly more effective in con-
trolling inﬂammation or reducing PCME than the weak
steroids.
Five different NSAIDs were used in the included studies.
Diclofenac was used in 7 studies,17e19,23,27e29 ketorolac
was used in 4 studies,19,21,22,30 bromfenac was used in 3
studies,20,25,31 nepafenac was used in 1 study,26 and
indomethacin was used in 1 study.24 Our meta-analyses
were not designed to determine which NSAID is most
effective. Other studies have compared the effect of different
NSAIDs. Diclofenac has been reported to be more effective
than ﬂurbiprofen and indomethacin in controlling inﬂam-
mation,39 whereas no difference was found for diclofenac
versus ketorolac.40,41 Ketorolac and nepafenac seem1922equally effective in controlling intraocular inﬂammation42
and preventing PCME.43 Ketorolac 0.4% reaches higher
aqueous humor concentration and lower prostaglandin
level than bromfenac 0.09% in patients with cataract
randomized to either regimen.44 Thus, we do not have
evidence to recommend 1 type of NSAID over any other
type of NSAID.
Our study did not evaluate when the prophylactic treat-
ment should be initiated. A few studies have compared
starting NSAIDs 1 to 3 days before surgery versus on the
day of surgery or the day after surgery. Preoperative
administration of ketorolac45 and diclofenac46 was
signiﬁcantly more effective in controlling inﬂammation
than administration starting the day of surgery or the day
after surgery. Furthermore, the risk of PCME was lower if
NSAIDs were administered before surgery.45,47 Thus, it
seems advisable to start NSAIDs 1 to 3 days before planned
surgery.
Patients with diabetes mellitus comprise a subgroup of
patients in whom special attention should be paid to reduce
the risk of macular edema after cataract surgery. A study
found that the foveal thickness increased more in patients
with worse diabetic retinopathy and that 22% of patients
had PCME.48 Our study was not aimed at evaluating PCME
in patients with diabetic mellitus, and no speciﬁc
recommendations can be given concerning the use of
steroids or NSAIDs in patients with diabetes mellitus.
Although control of postoperative inﬂammation and
prophylaxis of PCME are important in ensuring a successful
outcome after cataract surgery, current guidelines49,50 do not
provide speciﬁc recommendations concerning the post-
operative management of inﬂammation and prevention of
cystoid macular edema.Clinical Recommendation
Topical NSAIDs are more effective than topical steroids in
preventing inﬂammation and reducing the prevalence of
PCME after uncomplicated phacoemulsiﬁcation with pos-
terior chamber intraocular lens implantation. We did not
ﬁnd any indication that the use of topical NSAIDs was
associated with a higher risk of adverse events than topical
steroids nor was there any difference in the visual outcome.
The IOP was higher in patients randomized to topical
steroids. We recommend using topical NSAIDs after
cataract surgery to prevent inﬂammation and macular
edema.
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